BR112021020681A2 - Agonista de molécula pequena de fxr e método de preparação para o mesmo e uso do mesmo - Google Patents
Agonista de molécula pequena de fxr e método de preparação para o mesmo e uso do mesmoInfo
- Publication number
- BR112021020681A2 BR112021020681A2 BR112021020681A BR112021020681A BR112021020681A2 BR 112021020681 A2 BR112021020681 A2 BR 112021020681A2 BR 112021020681 A BR112021020681 A BR 112021020681A BR 112021020681 A BR112021020681 A BR 112021020681A BR 112021020681 A2 BR112021020681 A2 BR 112021020681A2
- Authority
- BR
- Brazil
- Prior art keywords
- small molecule
- preparation therefor
- fxr agonist
- fxr
- molecule fxr
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000003384 small molecules Chemical class 0.000 title abstract 3
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 2
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
agonista de molécula pequena de fxr e método de preparação para o mesmo e uso do mesmo. um agonista de molécula pequena de fxr e um método de preparação para o mesmo e um uso do mesmo, tendo uma estrutura conforme mostrada na fórmula (i). o composto representado pela fórmula (i) tem atividade agonística de fxr e é capaz de preparar fármacos para tratamento de doenças relacionadas a fxr.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910319757 | 2019-04-19 | ||
CN201910969552.6A CN111825667B (zh) | 2019-04-19 | 2019-10-12 | Fxr小分子激动剂及其制备方法和用途 |
PCT/CN2020/085713 WO2020211872A1 (zh) | 2019-04-19 | 2020-04-20 | Fxr小分子激动剂及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021020681A2 true BR112021020681A2 (pt) | 2021-12-07 |
Family
ID=72837054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021020681A BR112021020681A2 (pt) | 2019-04-19 | 2020-04-20 | Agonista de molécula pequena de fxr e método de preparação para o mesmo e uso do mesmo |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220213083A1 (pt) |
EP (1) | EP3957640A4 (pt) |
JP (1) | JP7398605B2 (pt) |
KR (1) | KR20220003558A (pt) |
BR (1) | BR112021020681A2 (pt) |
IL (1) | IL287159A (pt) |
MX (1) | MX2021012750A (pt) |
SG (1) | SG11202111502XA (pt) |
WO (1) | WO2020211872A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3159163A1 (en) | 2020-01-15 | 2021-07-22 | Raphael Darteil | Use of fxr agonists for treating an infection by hepatitis d virus |
CN114315830A (zh) * | 2020-09-30 | 2022-04-12 | 中国科学院上海药物研究所 | Fxr小分子激动剂及其制备方法和用途 |
CN116887827A (zh) * | 2020-12-30 | 2023-10-13 | 拓臻制药公司 | 用于调节fxr的化合物和方法 |
MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強 |
JP7450951B2 (ja) * | 2022-02-17 | 2024-03-18 | カスケード ファーマシューティカルズ、インコーポレーテッド | 新型fxr小分子作動剤の製造およびその使用 |
EP4245365A1 (en) * | 2022-03-16 | 2023-09-20 | Cascade Pharmaceuticals, Inc. | A fxr small molecule agonist, the preparation and use thereof |
US20230295141A1 (en) * | 2022-03-17 | 2023-09-21 | Cascade Pharmaceuticals, Inc. | Fxr small molecule agonist, the preparation and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012087521A1 (en) | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
JP2014500318A (ja) | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ファルネソイドx受容体を調節するための組成物および方法 |
EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
MA55632A (fr) * | 2016-08-23 | 2022-02-16 | Ardelyx Inc | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
CN107973790A (zh) * | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
-
2020
- 2020-04-20 MX MX2021012750A patent/MX2021012750A/es unknown
- 2020-04-20 EP EP20791301.3A patent/EP3957640A4/en active Pending
- 2020-04-20 BR BR112021020681A patent/BR112021020681A2/pt unknown
- 2020-04-20 SG SG11202111502XA patent/SG11202111502XA/en unknown
- 2020-04-20 WO PCT/CN2020/085713 patent/WO2020211872A1/zh active Application Filing
- 2020-04-20 US US17/603,823 patent/US20220213083A1/en active Pending
- 2020-04-20 KR KR1020217037613A patent/KR20220003558A/ko not_active Application Discontinuation
- 2020-04-20 JP JP2021562184A patent/JP7398605B2/ja active Active
-
2021
- 2021-10-11 IL IL287159A patent/IL287159A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3957640A4 (en) | 2022-12-14 |
JP7398605B2 (ja) | 2023-12-15 |
SG11202111502XA (en) | 2021-11-29 |
WO2020211872A1 (zh) | 2020-10-22 |
KR20220003558A (ko) | 2022-01-10 |
IL287159A (en) | 2021-12-01 |
US20220213083A1 (en) | 2022-07-07 |
EP3957640A1 (en) | 2022-02-23 |
JP2022529296A (ja) | 2022-06-20 |
MX2021012750A (es) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021020681A2 (pt) | Agonista de molécula pequena de fxr e método de preparação para o mesmo e uso do mesmo | |
NI201900041A (es) | 1, 2, 4-triazolonas 2, 4, 5-trisustituidas | |
NI201500142A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
ECSP18082774A (es) | Derivados aromáticos de sulfonamida | |
NI201700073A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
TR201901312T4 (tr) | Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri. | |
BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
BR112016028818A2 (pt) | composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo. | |
BR112017023764A2 (pt) | derivados de ciclohexano substituído por amido | |
AR099354A1 (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos | |
BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
BR112016013734A2 (pt) | Composto, composição farmacêutica, kit, e uso de um composto | |
BR112016028814A2 (pt) | ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo? | |
BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
EA201890570A1 (ru) | [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль | |
BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
BR112014009190A2 (pt) | formulação, uso de uma formulação, e, processo para a preparação de uma formulação | |
BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
BR112016007620A2 (pt) | composto, medicamento, e, uso de um composto | |
BR112022001568A2 (pt) | Composto, método para preparação do composto, composição farmacêutica, e, uso do composto | |
BR112021024325A2 (pt) | Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
MY197561A (en) | Composition for increasing expression of pgc-1? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) ; VAN ANDEL RESEARCH INSTITUTE. (US) |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |